Novel high efficiency library-identified aav vectors
US-2018265863-A1 · Sep 20, 2018 · US
Engineering AAV
US12565685B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12565685-B2 |
| Application number | US-202418630996-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 9, 2024 |
| Priority date | Apr 26, 2019 |
| Publication date | Mar 3, 2026 |
| Grant date | Mar 3, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides methods and compositions to develop AAV capsids with a desired characteristic compared to a natural AAV serotype. These capsids are useful, for example, for the delivery of genome engineering molecules and gene therapy molecules for the treatment of a subject in need thereof.
First claim
Opening claim text (preview).
What is claimed is: 1 . A capsid protein comprising at least 4 contiguous amino acids of an amino acid sequence set forth in any of SEQ ID NO: 1-32 or at least 4 contiguous amino acids of an amino acid sequence set forth in any of SEQ ID NO: 68-110. 2 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 11. 3 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 15. 4 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 69. 5 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 70. 6 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 71. 7 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 72. 8 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 73. 9 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 74. 10 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 75. 11 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 76. 12 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 77. 13 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 78. 14 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 79. 15 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 80. 16 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 83. 17 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 90. 18 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 99. 19 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 108. 20 . The capsid protein of claim 1 , wherein the capsid protein comprises SEQ ID NO: 110.
Assignees
Inventors
Classifications
Identifying library members by means of a tag, label, or other readable or detectable entity associated with the library members, e.g. decoding processes · CPC title
Nucleic acid dedicated to use as a hidden marker/bar code, e.g. inclusion of nucleic acids to mark art objects or animals · CPC title
Dependovirus, e.g. adenoassociated viruses · CPC title
Viral vectors · CPC title
having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12565685B2 cover?
- The present disclosure provides methods and compositions to develop AAV capsids with a desired characteristic compared to a natural AAV serotype. These capsids are useful, for example, for the delivery of genome engineering molecules and gene therapy molecules for the treatment of a subject in need thereof.
- Who is the assignee on this patent?
- Sangamo Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N15/1058. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 03 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).